Abstracts At European Society of Cardiology Highlight Longer Term Benefits of EECP.

Business Editors, Health/Medical Writers

WESTBURY, N.Y.--(BUSINESS WIRE)--August 31, 2000

Vasomedical, Inc. (Nasdaq SmallCap: VASO) announced today that the results of three studies discussing the Company's EECP(R) (Enhanced External Counterpulsation) system were presented at the 22nd Annual Congress of the European Society of Cardiology (ESC) in Amsterdam August 26-30, 2000. The results, in two of the three studies, point to a sustained reduction of angina at six months post-treatment.

An abstract presented Wednesday, August 30th, by Ozlem Soran, MD, of the University of Pittsburgh, showed that those patients with poor left ventricular function do as well with EECP as their less sick counterparts. The patient data for this study had been collected by the International EECP Patient Registry at the University of Pittsburgh Graduate School of Public Health. The study, entitled "Six month outcome of patients with left ventricular dysfunction treated with enhanced external counterpulsation for chronic angina," and which will also be presented at the upcoming meeting of the Heart Failure Society of America to be held in Florida September 10-13, looked at a cohort of more than 1,000 patients, 27% of whom had severe left ventricular dysfunction (LVD). The remaining patients had preserved left ventricular function. According to the study, both groups showed a significant reduction in angina and nitroglycerine use immediately following treatment and at six months post-treatment. In addition, a considerable portion of the LVD patients had a history of congestive heart failure (CHF). Vasomedical recently received approval from the FDA to proceed with a multicenter controlled study designed to test the effectiveness of EECP in patients with CHF.

Also presented at this years ESC was an abstract entitled, "Improved stress radionuclide coronary perfusion and exercise capacity after enhanced external counterpulsation," by lead author, Dr. T.P. Stys of the State University of New York at Stony Brook. Data from this study showed that, among the individuals who underwent EECP therapy, many of whom had multivessel disease, had experienced a prior heart attack, or had undergone balloon angioplasty or bypass surgery, there was both an improvement in blood flow to the heart muscle and an increase in exercise tolerance. Commenting on the abstract, John Strobeck, MD, Medical Director of the Heart-Lung Center in Hawthorne, New Jersey, said, "The evidence in this 217 patient study suggests, as previous publications have, that the improved blood flow to the heart muscle we see with EECP may be related to the recruitment of collateral circulation brought about by the widening of blood vessels in areas of the heart which had been previously under-perfused or the release of growth factors resulting in angiogenesis, the development of new blood vessels."

A third abstract entitled, "Does optimal diastolic augmentation predict clinical benefit from enhanced external counterpulsation ? - Data from the International EECP Patient Registry," lead author, Dr. Andrew Michaels of the University of California in San Francisco, suggests that higher levels of diastolic augmentation, such as those which may be achieved using the proprietary timing algorithms built into Vasomedical's EECP system, are indicative of better clinical outcomes. Data from more than one thousand patients were analyzed in reaching the study's conclusions.

The ESC is the largest forum in Europe presenting the latest developments in research and clinical cardiology. ESC membership is approximately 27,700 and this year's Congress drew in excess of 12,000 participants. D. Michael Deignan, CEO of Vasomedical, who attended this week's congress in Amsterdam, stated, "Vasomedical's presence at this year's ESC, combined with the presentation of several important studies have brought increased awareness and acceptance of EECP therapy. The Company will shortly be putting in place the infrastructure to allow it to more rapidly expand its direct presence in Europe and the Middle East. This, combined with a number of studies currently under way in different countries, will hasten the establishment of reimbursement for the therapy in these areas."

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external counterpulsation systems based on the Company's proprietary technology currently indicated for use in cases of angina, cardiogenic shock and acute myocardial infarction. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers, including the Beth Israel Medical Center - New York City, Christ Hospital and Medical Center, the Cleveland Clinic JFK Medical Center-Atlantis, FL, Kaiser Permanente of Denver, the Mayo Clinic, the Miami Heart Institute and the Ochsner Foundation Hospital, as well as medical centers affiliated with Columbia University, the University of Pittsburgh, the University of California at San Diego, the University of California at San Francisco, University of Florida at Gainesville, State University of New York at Stony Brook and the University of Virginia. The Company provides hospitals, clinics and private practices with EECP(R) equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believe," "estimate," "expect" and "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.